Lutetium (177Lu) vipivotide tetraxetan
镥[177Lu]特昔维匹肽PSMA-targeted radioligand therapy newly added to the 2026 Commercial Health Insurance Innovative Drug List (#28) for PSMA-positive mCRPC.
China Approval (NMPA)
Pending VerificationReimbursement catalog entries for this drug are verified from NHSA official PDFs. Individual NMPA registration certificate numbers (国药准字) and approval dates are queued for incremental verification.
National Reimbursement
Not ListedNot included in the 2025 or 2026 National Reimbursement Drug List (basic medical insurance).
Commercial Insurance List
Announced · Effective Jan 1, 2027- 2026 List Entry
- #28 · 派威妥
- Validity Period
- 2027-01-01 to 2028-12-31
- MAH / Authorized Entity
- Novartis Pharma Schweiz AG · 诺华医药科技(浙江)有限公司
- Listed Indication Scope
- Adult PSMA-positive mCRPC: (1) After progression on ARPI and eligible to delay chemotherapy; (2) After progression on ARPI and taxane-based chemotherapy.
Catalog inclusion only. Actual reimbursement depends on individual commercial health insurance policy contracts.
Approved Products, Dosage Forms & Approval Numbers
0 verified NMPA recordsChange Timeline
- (2027-01-01)Commercial List· Catalog published: Nov 14, 2026
2026 Commercial List · Newly Added (#28)
Adult PSMA-positive mCRPC: (1) After progression on ARPI and eligible to delay chemotherapy; (2) After progression on ARPI and taxane-based chemotherapy.
Chinese original: 本品适用于以下成人患者:1.既往接受雄激素受体通路抑制剂(ARPI)后疾病进展且适合延迟化疗的前列腺特异性膜抗原(PSMA)阳性转移性去势抵抗性前列腺癌(mCRPC);2.既往接受雄激素受体通路抑制和紫杉类化疗后疾病进展的PSMA阳性mCRPC。
NHSA · PDF p.5Verified 2026-11-20
Verified Names & Aliases
Every English INN, Chinese generic name, brand name, and R&D code is recorded with its source.
Primary Sources for This Record
- NHSAPublished 2026-11-14商业健康保险创新药品目录(2026年)Retrieved 2026-11-20
- WHO世界卫生组织国际非专利药名(INN)指南Retrieved 2026-11-20